Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

immunocept.com

Founded Year

2017

Stage

Acquired | Acquired

About Immunocept Medical Products

Immunocept Medical Partners develops medical products and therapies for cytokine storm syrndome, destructive system inflammaiont resulting from infection, trauma, brain death, and immune cancer therapy.

Immunocept Medical Products Headquarters Location

1800 Lawrence Street Suite 306

Denver, Colorado, 80202,

United States

(972

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Immunocept Medical Products News

Immunocept acquired by CytoPherx, graduates from Innosphere

Jul 30, 2018

FORT COLLINS -- Innosphere  client company  Immunocept Medical Products has met its graduation goal of achieving a successful acquisition by CytoPherx. The acquisition with CytoPherx will ensure a synergistic approach to branding, manufacturing and customer call points, Immunocept said. “This merger enables the immediate launch of Immunocept’s FDA-cleared blood filter, creating revenues and early brand recognition for the family of products to solve several real-world problems,” said Charles J. Fisher, Jr., CytoPherx CEO. CytoPherx is currently in the process of rebranding as SeaStar Medical to give a fresh start to both companies. Immunocept Medical Products is based in Denver and recently received FDA clearance to market its CLR 2.0 blood filter for use in patients with acute kidney injury, pulmonary edema, or congestive heart failure. “Both companies coming together strengthens IP protection with the combined patent portfolios,” said Chris Jaynes, SeaStar Medical chief commercialization officer and former Immunocept CEO. “Combined, there are 62 issued and pending US patents covering nearly everything that can be done with hollow fiber membranes in the acute inflammation and multi-organ failure therapeutic space. “Our technologies greatly improve efficiencies and lower costs of manufacturing.” The acquisition further strengthens the CytoPherx technology, known as the Selective Cytopheric Device (SCD), developed to treat very ill patients with acute kidney injury and multiple organ failures. Both the Immunocept and the CytoPherx blood filters are designed to fit onto standard, hospital ICU-based CRRT equipment, either independently or together, for improved patient benefit. Additionally, both devices will be deployed in hospital ICUs (pediatric and adult) by the same physicians for the same patients. Based in San Diego with laboratories in Ann Arbor, MI, the newly merged company will rebrand itself “SeaStar Medical,” paying tribute to a unique local creature that has regenerative, anti-inflammatory and cancer tumor-killing properties. CytoPherx, Inc. is a medical device company offering a proprietary selective cytopheresis system for inflammation-based diseases and conditions.

  • When was Immunocept Medical Products founded?

    Immunocept Medical Products was founded in 2017.

  • Where is Immunocept Medical Products's headquarters?

    Immunocept Medical Products's headquarters is located at 1800 Lawrence Street, Denver.

  • What is Immunocept Medical Products's latest funding round?

    Immunocept Medical Products's latest funding round is Acquired.

  • Who are the investors of Immunocept Medical Products?

    Investors of Immunocept Medical Products include CytoPherx.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.